The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study
2024; Elsevier BV; Volume: 24; Issue: 5 Linguagem: Inglês
10.1016/s1473-3099(23)00816-2
ISSN1474-4457
AutoresNora Schmit, Hillary M. Topazian, Hamtandi Magloire Natama, Duncan Bellamy, Ousmane Traoré, M. Athanase Somé, Toussaint Rouamba, Marc Christian Tahita, Massa dit Achille Bonko, Aboubakary Sourabié, Hermann Sorgho, Lisa Stockdale, Samuel Provstgaard-Morys, Jeremy Aboagye, Danielle Woods, Katerina Rapi, Mehreen S. Datoo, Fernando Ramos Lopez, Giovanni Charles, Kelly McCain, Jean‐Bosco Ouédraogo, Mainga Hamaluba, Ally Olotu, Alassane Dicko, Halidou Tinto, Adrian V. S. Hill, Katie Ewer, Azra C. Ghani, Peter Winskill,
Tópico(s)Viral Infections and Outbreaks Research
ResumoThe R21/Matrix-M vaccine has demonstrated high efficacy against Plasmodium falciparum clinical malaria in children in sub-Saharan Africa. Using trial data, we aimed to estimate the public health impact and cost-effectiveness of vaccine introduction across sub-Saharan Africa.
Referência(s)